MedTrace Logo

Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures

NCT02195622 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2019-03-11

Study results available
· View outcomes & findings →

Summary

To compare efficiency, in terms of tissue morcellation and removal time, of two commercially available FDA-approved morcellators: the VersaCut and the Piranha in subjects undergoing HoLEP procedure for benign prostatic hyperplasia (BPH).

Conditions

  • Benign Prostatic Hypertrophy Requiring Surgical Intervention

Interventions

DEVICE

Lumenis VersaCut Morcellator

DEVICE

Wolf Piranha Morcellator

Sponsors & Collaborators

  • Richard Wolf Medical Instruments Corporation (RWMIC)

    collaborator UNKNOWN

  • Indiana Kidney Stone Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-01-31
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02195622 on ClinicalTrials.gov